SFRP1 and WIF1 are Wnt antagonists that can block Wnt/β-catenin signaling [206], whereas IC-2 is a novel Wnt inhibitor that can reduce CD44+ populations and the formation of spheres in HCC [191]. This evidence concerns the gene SFRP1 and hepatocellular carcinoma.